Tag: Sotagliflozin

1. Sotagliflozin treatment was shown to increase the days-alive-and-out-of-hospital compared to placebo in patients with type 2 diabetes and heart failure. 2. Sotagliflozin treatment was shown to significantly decrease the rate of days dead compared to the placebo treatment. Evidence Rating Level: 1 (Excellent) Study Rundown: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have...
1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure in patients with diabetes and recent worsening heart failure compared to placebo. 2. Sotagliflozin was shown to be similar in the percentage of patients with adverse...
1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure in patients with diabetes and recent worsening heart failure compared to placebo. 2. Sotagliflozin was shown to be similar in the percentage of patients with adverse...